The ability to induce somatic cells to pluripotency by ectopic expression of defined transcription factors (e.g. KLF-4, OCT4, SOX2, c-MYC, or KOSM) has transformed the future of regenerative medicine. Here we report somatic cell reprogramming of human umbilical vein endothelial cells (HUVECs), yielding induced pluripotent stem (iPS) cells with the fastest kinetics, and one of the highest reprogramming efficiencies for a human somatic cell to date. HUVEC-derived iPS (Huv-iPS) cell colonies appeared as early as 6 days after a single KOSM infection, and were generated with a 2.5-3% reprogramming efficiency. Furthermore, when HUVEC reprogramming was performed under hypoxic conditions in the presence of a TGF-beta family signaling inhibitor, colony formation increased an additional ∼2.5-fold over standard conditions. Huv-iPS cells were indistinguishable from human embryonic stem (ES) cells with regards to morphology, pluripotent marker expression, and their ability to generate all embryonic germ layers in vitro and in vivo. The high efficiency and rapid kinetics of Huv-iPS cell formation, coupled with the ease by which HUVECs can be collected, expanded and stored, make these cells an attractive somatic source for therapeutic application, and for studying the reprogramming process.
The ability to induce somatic cells to pluripotency by ectopic expression of defined transcription factors (e.g. KLF-4, OCT4, SOX2, c-MYC, or KOSM) has transformed the future of regenerative medicine. Here we report somatic cell reprogramming of humanumbilical vein endothelial cells (HUVECs), yielding induced pluripotent stem (iPS) cells with the fastest kinetics, and one of the highest reprogramming efficiencies for a human somatic cell to date. HUVEC-derived iPS (Huv-iPS) cell colonies appeared as early as 6 days after a single KOSM infection, and were generated with a 2.5-3% reprogramming efficiency. Furthermore, when HUVEC reprogramming was performed under hypoxic conditions in the presence of a TGF-beta family signaling inhibitor, colony formation increased an additional ∼2.5-fold over standard conditions. Huv-iPS cells were indistinguishable from human embryonic stem (ES) cells with regards to morphology, pluripotent marker expression, and their ability to generate all embryonic germ layers in vitro and in vivo. The high efficiency and rapid kinetics of Huv-iPS cell formation, coupled with the ease by which HUVECs can be collected, expanded and stored, make these cells an attractive somatic source for therapeutic application, and for studying the reprogramming process.
Seminal studies demonstrated that fibroblasts could be reprogrammed to pluripotency
by ectopic expression of defined factors [1]–[3]. Somatic cell reprogramming has now
been performed with numerous somatic sources with variable kinetics and efficiencies
[4], [5]. Among these,
recent reports have demonstrated that iPS cells can be generated from human
peripheral blood samples, advancing practical methods of obtaining patient-specific
iPS cells [6]–[8]. However, while the accessibility of this somatic cell
source provides an advantage, reprogramming blood samples is not an efficient
(∼0.001–0.1%) or rapid (∼1 month) process [6]–[8]. More importantly, primary blood
samples cannot be continually passaged or easily manipulated, resulting in limited
flexibility to generate iPS cells.In contrast, human fibroblasts are amenable to culture manipulations, but are also
inefficient (<0.01%) and slow (∼1 month) in undergoing reprogramming
[2], [3]. We therefore sought
to find a more practical cell type that could be readily isolated and expanded, yet
could reprogram quickly and efficiently. Here we report the rapid reprogramming of
HUVECs, with an efficiency approximately 300-fold higher than human fibroblasts
[2], [3]. The methods by
which HUVECs can be readily obtained in large quantities without purification steps
[9], coupled
with their fast and efficient rate of reprogramming, makes this somatic cell source
practical for therapeutic application, and for studying the mechanisms governing
reprogramming.
Methods
iPS cell generation
Keratinocytes or HUVECs (Lonza) were infected at similar passage (generally at p2
or p3) with equivalent ratios of retroviruses encoding KOSM by spinfection at
800 g for 1 hour at RT in the presence of polybrene (8 µg/ml). Cells were
replated onto MEFs (Millipore) in their respective media, and switched to ES
cell medium for iPS cell colony formation. Resulting iPS cell colonies were
either manually picked for iPS cell line derivation (∼10–12 days after
infection), or stained for Nanog as described (∼14–20 days after
infection, to enable iPS cell colony formation from keratinocyte controls).
Reprogramming efficiencies were then determined by calculating the number of
Nanog positive colonies as a percentage of GFP positive cells. For reprogramming
experiments performed in hypoxic conditions, cells were placed in 5%
02 incubators 4 days after the initial infection (i.e. when the
cells were switched to ES cell medium) where they remained for the duration of
the assay. For TGF-beta family signaling inhibitor reprogramming experiments,
cells were treated daily with 10 µM SB431532 (Sigma) from day 4 to day 10
after the initial infection, and then were treated with ES cell media without
SB431532 for the duration of the assay.
Cell lines and culture
Human neonatal keratinocytes (Lonza) and HUVECs (Lonza) were grown according to
manufacturer's recommendations. 293T cells (ATCC) were cultured in DMEM
(Invitrogen) containing 10% fetal calf serum (FCS). Human H1 or H9ES
cell lines (Wicell) were cultured as previously described [10]–[12]. iPS cell
lines obtained from keratinocytes [13] (KiPS4F2, KiPS4FA, KiPS4FB),
astrocytes [14]
(ASTiPS4F5) or fibroblasts [15] (FiPS4F5) were used as controls, and were all fully
characterized using similar methodologies and criteria as described herein.
Plasmids and virus preparation
The following moloney murine leukemia virus-based retroviral vectors were
obtained from Addgene: pMXs-hOCT4, pMXs-hSOX2, pMXs-hKLF4 and pMXs-hc-Myc
(plasmids 17217, 17218, 17219 and 17220 respectively). pMXs-eGFP was kindly
provided by Dr. Teruhisa Kawamura (Gene Expression Laboratory, The Salk
Institute, La Jolla, CA). Packaging plasmids (pCMV-gag-pol-PA and pCMV-VSVg)
were kindly provided by Dr. Gerald Pao, Laboratory of Genetics, The Salk
Institute, La Jolla, CA. Retrovirus was collected 24 hours following
cotransfection of plasmids in 293T cells using Lipofectamine (Invitrogen) in
accordance with manufacturer's recommendations.
Immunofluorescence and immunohistochemistry
For the immunohistochemical detection of Nanog, cells were first fixed with
4% formaldehyde in PBS for 15 minutes at room temperature (RT). Following
washing in PBS, cells were incubated in 0.4% Triton-X100/PBS at RT for 10
minutes. A rabbit anti-humanNanog antibody (1∶500, Abcam) was diluted in
PBS containing 1% BSA (PBS/BSA) and was used for overnight incubation at
4°C. Cells were then washed in PBS/BSA, and incubated with a secondary
biotin-conjugated anti-rabbit antibody (1∶2000) for an additional 2 hours
at RT. After washing in PBS/BSA, cells were incubated at RT with
streptavidin-HRP (Vector, 1∶1000) for 2 hours, and a DAB substrate kit for
peroxidase (Vector, SK-4100) was used to develop the staining.For standard immunofluorescence, cells were fixed and permeabilized as described,
followed by blocking in PBS/BSA containing 5% FCS for 1 hour at RT.
Antibodies to FoxA2 (R&D), Tuj-1 (Covance), alpha smooth muscle actin (ASMA,
Sigma) were diluted in PBS/BSA and used in overnight incubations at 4°C,
followed by incubation with fluorescently-conjugated secondary antibodies
(AlexaFluor 488 or AlexaFluor 568, Invitrogen) for 2 hours at RT.
4,6-Diamidino-2-phenylindole (DAPI) was used to visualize nuclei at a
concentration of 10 µg/ml in PBS. Additional immunofluorescence, and
hematoxylin and eosin staining, was performed as previously described [13].
Flow cytometry
Cells were collected with TrypLE (Invitrogen), resuspended in PBS containing
1% BSA (PBS/BSA) and labeled with fluorescently conjugated antibodies to
Tra-1-60 (BD Pharmingen), Tra-1-81 (Stemgent), SSEA-4 (BD Pharmingen), CD34 (BD
Pharmingen), CD45 (BD Pharmingen), CD31 (BD Pharmingen), or the appropriate
isotype controls. Samples were analyzed by flow cytometry on a FACScan
(Becton-Dickinson), and figures generated using FlowJo software (TreeStar
Inc).
Real-time PCR
To determine gene expression levels, total RNA was first isolated using Trizol
Reagent (Invitrogen), and reverse transcribed using the SuperScript II Reverse
Transcriptase kit (Invitrogen), according to the manufacturer's
recommendations. Real-time PCR analysis was performed using the SYBR-Green PCR
Master mix (Applied Biosystems). The expression values of individual genes were
normalized to GAPDH, and are shown relative to control samples
as indicated. See Table 1
for a complete list of primers.
Table 1
List of primers.
Primer
Sequence (5′ to 3′)
Application
OCT4 total-F
GGAGGAAGCTGACAACAATGAAA
qPCR
OCT4 total-R
GGCCTGCACGAGGGTTT
qPCR
SOX2 total-F
TGCGAGCGCTGCACAT
qPCR
SOX2 total-R
TCATGAGCGTCTTGGTTTTCC
qPCR
KLF4 total-F
CGAACCCACACAGGTGAGAA
qPCR
KLF4 total-R
GAGCGGGCGGCGAATTTCCAT
qPCR
c-MYC total-F
AGGGTCAAGTTGGACAGTGTCA
qPCR
c-MYC total-R
TGGTCGATTTTCGGTTGTTG
qPCR
OCT4 end-F
GGGTTTTTGGGATTAAGTTCTTCA
qPCR
OCT4 end-R
GCCCCCACCCTTTGTGTT
qPCR
SOX2 end-F
CAAAAATGGCCATGCAGGTT
qPCR
SOX2 end-R
AGTTGGGATCGAACAAAAGCTATT
qPCR
KLF4 end-F
AGCCTAATTGATGGTGCTTGGT
qPCR
KLF4 end-R
TTGAAAACTTTGGCTTCCTTGTT
qPCR
c-MYC end-F
CGGGCGGGCACTTTG
qPCR
c-MYC end-R
GGAGAGTCGCGTCCTTGCT
qPCR
GAPDH-F
GGACTCATGACCACAGTCCATGCC
qPCR
GAPDH-R
TCAGGGATGACCTTGCCCACAG
qPCR
OCT4 genomic-F
AGCGATCAAGCAGCGACTAT
qPCR
OCT4 genomic-R
GTGAAGTGAGGGCTCCCATA
qPCR
SOX2 genomic-F
AACCCCAAGATGCACAACTC
qPCR
SOX2 genomic-R
GCTTAGCCTCGTCGATGAAC
qPCR
KLF4 genomic-F
GTCTCTTCGTGCACCCACTT
qPCR
KLF4 genomic-R
TGCTCAGCACTTCCTCAAGA
qPCR
c-MYC genomic-F
CCCTCAACGTTAGCTTCACC
qPCR
c-MYC genomic-R
CAGCAGCTCGAATTTCTTCC
qPCR
GAPDH genomic-F
ACCCAGAAGACTGTGGATGG
qPCR
GAPDH genomic-R
TTCAGCTCAGGGATGACCTT
qPCR
For the stem cell array analysis between ES cells and the Huv-iPS cell lines,
real-time PCR of a selected number of genes based on the Human Stem RT2 Cell
Array (SuperArray Bioscience Corporation) was performed. These genes
differentially discriminate between pluripotent and somatic cell types. For a
detailed description of the genes and primer sets used for this analysis see
Ruiz et al [14].In order to determine the copy numbers of transgenes introduced by reprogramming,
a quantitative real-time PCR method was developed to detect both endogenous and
transgenic numbers of four reprogramming factors (OCT4,
SOX2, KLF-4, c-MYC).
Briefly, primer sets specifically detecting the coding sequence within a single
exon were designed for each reprogramming factor, and tested for both ES cell
genomic DNA (gDNA) and reprogramming retroviral vectors. High quality gDNA
samples were prepared using QIAGEN DNeasy Blood & Tissue Kit (QIAGEN), and
measured by NanoDrop 8000 Spectrophotometer (Thermo Scientific). For each
reaction, 10 ng gDNA from each sample were run in triplicate along with four
points of ES cell gDNA standard curve templates made by 10-fold serial dilutions
(from 100 ng to 0.1 ng) to ensure adequate amplification efficiency
(>90%). Levels of each reprogramming factor were normalized to
GAPDH for each sample, and calculated relative to the
endogenous levels in ES cells (2 copies of each factor per genome). The results
were presented as means +/− standard deviations of both endogenous
and transgenic copy numbers. All PCR reactions were performed using the
SYBR-Green PCR Master mix on the ViiA 7 Real-time PCR system (Applied
Biosystems) in accordance to the manufacturer's instructions, and were
repeated three times. See Table
1 for a complete list of primers.
In vitro differentiation
For embryoid body (EB) differentiation, ES or Huv-iPS cell colonies growing on
MEFs (Millipore) were loosely detached by dispase treatment, washed and
resuspended in EB media (DMEM/F12 containing 10% FCS (Atlanta
Biologicals), 0.5 mM L-glutamine, 0.1 mM non-essential amino acids and 55
µM β-mercaptoethanol). EBs were maintained on low attachment plates
and replenished daily with fresh EB media. After 4 days, EBs were plated on
gelatin-coated plates, allowed to differentiate for another 10 days in EB media,
fixed and stained as described.
Teratoma assay and karyotype analysis
To test for teratoma formation, iPS cell lines were injected into severe combined
immunodeficientmice (NOD.Cg-Prkdc/SzJ; Jackson Laboratories). Briefly,
∼106 iPS cells in ∼50 µL of ES cell medium were
injected into the kidney capsule or testes of anesthetized mice. Mice were then
monitored for formation of teratomas, and euthanized ∼6–12 weeks after
injection. Collected teratomas were analyzed by immunofluorescence or
hematoxylin and eosin staining as previously described [13]. All mouse experimental
procedures were performed and approved (accepted protocol number 08–025)
by The Salk Institute Institutional Animal Care and Use Committee (IACUC). All
Huv-iPS cell lines were karyotyped by Wicell.
Statistical analysis
Results are shown as mean values ± standard deviation (SD) or standard
error of the mean (SEM) as indicated. The values obtained for the stem cell
array were analyzed using the Pearson correlation coefficient as a measure of
similarity. Remaining statistics were performed using unpaired two-tailed
Student's t-tests. P values<0.05 were
considered statistically significant.
Results
HUVECs were transduced with retroviruses encoding KOSM to induce somatic cell
reprogramming (Figure 1A).
Retroviral infections with GFP were included to assess infection efficiency, and to
monitor transgene silencing [16]. We observed the appearance of colonies with an ES
cell-like morphology as early as 6 days after two serial KOSM infections (Figure 1B). In several cases,
these colonies were GFP negative, correlating with transgene silencing (Figure 1B). We next tested if a
single infection would be sufficient to elicit the production of iPS cells. To
assess the efficiency of HUVEC reprogramming, we performed parallel infection
experiments with keratinocytes, a human somatic cell type with one of the highest
reported reprogramming efficiencies to date [13]. HUVECs and keratinocytes were
infected in parallel with retroviruses encoding KOSM and GFP on day 0 (1X), or day 0
and day 1 (2X), equivalent numbers of GFP positive cells plated, and resulting
colonies stained for Nanog as an initial measure of pluripotency (Figure 2A, 2B). We routinely
observed >80% transduction efficiency for all conditions (Figure 2A). Following a single
KOSM infection, HUVECs displayed a 2.5–3% reprogramming efficiency,
whereas keratinocytes demonstrated an approximate 1% reprogramming
efficiency, in agreement with our previous findings (Figure 2C) [13]. Interestingly, two serial KOSM
infections decreased reprogramming efficiencies for both cell types, although more
strikingly for keratinocytes, and resulted in a more substantial efficiency
difference between HUVECs and keratinocytes (1X = 2.5–3
fold difference vs. 2X = 7–8 fold difference,
respectively; Figure 2C). These
results indicate that the number of infections should be taken into account when
determining reprogramming efficiencies, and suggest that the balance of viral
incorporation and tolerance to infection varies for somatic cell types. Of note,
HUVECs that had undergone additional freeze/thaws before infection, or had been
passaged repeatedly (e.g. 7–8 passages), still generated the high
reprogramming efficiencies indicated (Figure 2C).
Figure 1
Derivation of induced pluripotent cells from HUVECs.
HUVECs were retrovirally infected with KLF-4,
OCT4, SOX2 and c-MYC
(KOSM) to generate induced pluripotent stem cells (Huv-iPS4F). (A) Schematic
representation of the experimental strategy used to reprogram HUVECs. (B)
Infected HUVECs were plated onto mouse embryonic fibroblasts (MEFs) and
colony formation assessed. Retroviral transduction of GFP was included to
measure infection efficiency, and monitor silencing of transgenes during
reprogramming. Note the appearance of GFP negative colonies with an ES
cell-like morphology as early as 6 days after infection, as demonstrated by
tracking an individual colony (black arrow) from day 6 through day 11. An
example of an established Huv-iPS cell line grown in feeder-free conditions
is shown on the right. All images were acquired with a standard microscope
using a 20× objective; all fluorescent images shown were acquired with
the same exposure time.
Figure 2
Reprogramming of HUVECs is highly efficient.
(A) HUVECs and keratinocytes were infected in parallel with retroviruses
encoding KOSM and GFP. Shown are representative histograms of GFP expression
for each cell type 3 days after infection, as assessed by flow cytometry.
(B) Equivalent numbers of GFP positive cells were plated on MEFs, and a
representative example of immunohistochemical staining (of an individual
well from a 6-well plate) for Nanog of the resulting colonies is shown. MEF
feeder layers serve as an internal negative control for Nanog staining. (C)
HUVECs and keratinocytes (Ker) were infected in parallel (a single
infection, 1X, or two infections, 2X) plated, and stained for Nanog. Nanog
positive colonies were numerated and plotted as a percentage of GFP positive
cells, indicative of reprogramming efficiency. Results were quantified from
triplicate samples, and are representative of at least three independent
experiments. Error bars depict the standard error mean (SEM). (D) Equivalent
numbers of KOSM-infected HUVECs (1X infection) were plated and placed in
incubators containing 20% O2 (standard conditions) or
5% 02 (hypoxic conditions) in the presence or absence of
the TGF-beta family signaling inhibitor SB431532 (SB). The reprogramming
efficiencies relative to controls are shown. Results were quantified from
triplicate samples, and are representative of two independent experiments.
Error bars depict the SEM. *P<0.05.
Derivation of induced pluripotent cells from HUVECs.
HUVECs were retrovirally infected with KLF-4,
OCT4, SOX2 and c-MYC
(KOSM) to generate induced pluripotent stem cells (Huv-iPS4F). (A) Schematic
representation of the experimental strategy used to reprogram HUVECs. (B)
Infected HUVECs were plated onto mouse embryonic fibroblasts (MEFs) and
colony formation assessed. Retroviral transduction of GFP was included to
measure infection efficiency, and monitor silencing of transgenes during
reprogramming. Note the appearance of GFP negative colonies with an ES
cell-like morphology as early as 6 days after infection, as demonstrated by
tracking an individual colony (black arrow) from day 6 through day 11. An
example of an established Huv-iPS cell line grown in feeder-free conditions
is shown on the right. All images were acquired with a standard microscope
using a 20× objective; all fluorescent images shown were acquired with
the same exposure time.
Reprogramming of HUVECs is highly efficient.
(A) HUVECs and keratinocytes were infected in parallel with retroviruses
encoding KOSM and GFP. Shown are representative histograms of GFP expression
for each cell type 3 days after infection, as assessed by flow cytometry.
(B) Equivalent numbers of GFP positive cells were plated on MEFs, and a
representative example of immunohistochemical staining (of an individual
well from a 6-well plate) for Nanog of the resulting colonies is shown. MEF
feeder layers serve as an internal negative control for Nanog staining. (C)
HUVECs and keratinocytes (Ker) were infected in parallel (a single
infection, 1X, or two infections, 2X) plated, and stained for Nanog. Nanog
positive colonies were numerated and plotted as a percentage of GFP positive
cells, indicative of reprogramming efficiency. Results were quantified from
triplicate samples, and are representative of at least three independent
experiments. Error bars depict the standard error mean (SEM). (D) Equivalent
numbers of KOSM-infected HUVECs (1X infection) were plated and placed in
incubators containing 20% O2 (standard conditions) or
5% 02 (hypoxic conditions) in the presence or absence of
the TGF-beta family signaling inhibitor SB431532 (SB). The reprogramming
efficiencies relative to controls are shown. Results were quantified from
triplicate samples, and are representative of two independent experiments.
Error bars depict the SEM. *P<0.05.Previous studies have demonstrated that hypoxia or inhibition of TGF-beta family
signaling enhances iPS cell generation [17]–[19]. We next tested each of these
conditions, alone or in combination, in HUVEC-mediated colony formation. Performing
reprogramming under hypoxic conditions was sufficient to increase the reprogramming
efficiency compared to controls grown in standard 20% O2
conditions (Figure 2D). However,
treatment with the TGF-beta family signaling inhibitor SB431532 in combination with
hypoxic conditions further increased reprogramming ∼2.5-fold over controls
(Figure 2D).To characterize HUVEC-generated colonies, we manually picked ∼12 GFP negative
colonies 10–12 days after KOSM infection, and randomly chose three lines
(Huv-iPS4F1, Huv-iPS4F3, Huv-iPS4F6) for full characterization. We first evaluated
the expression of the reprogramming factors, following the initial infection, as
well as in the established Huv-iPS cell lines generated. Expression of
OCT4, SOX2, KLF-4 and
c-MYC was induced at similar levels following 3 days of
infection for both HUVECs and keratinocytes (Figure 3A). Individual Huv-iPS cell lines also
demonstrated endogenous OCT4, SOX2,
KLF-4 and c-MYC gene expression levels that
were similar to ES cell controls, and to the total (endogenous+transgene)
expression levels for each gene (Figure
3A). Although this is indicative of strong transgene silencing, minor
contribution from transgenes to the total expression of KLF-4 (each
line) or c-MYC (Huv-iPS4F3 cell line) was observed (Figure 3A). Furthermore, Huv-iPS
cells showed transgene copy numbers at comparable levels to other iPS cell lines
that had been generated using the same retroviral approach, but from less efficient
somatic sources such as fibroblasts (FiPS4F5), astrocytes (ASTiPS4F5), and
keratinocytes (KiPS4F2, KiPS4FA, KiPS4FB) (Figure 3B) [13]–[15]. Thus, the higher efficiency of
HUVECs to generate iPS cells is not likely due to differences in infection
efficiency or transgene integration, but to other as of yet undetermined mechanisms
of inducing pluripotency.
Figure 3
Reprogramming factor expression and transgene integration in Huv-iPS
cells.
(A) Gene expression levels of the endogenous and total levels of
OCT4, SOX2, KLF-4 and
c-MYC in Huv-iPS cell lines, ES cell controls (H1 and
H9 cell lines), somatic cells (keratinocytes and HUVECs) or somatic cells 3
days after KOSM infection. Individual real-time PCR reactions were
normalized to GAPDH, and plotted relative to the expression
level in HUVECs. Data are shown as the relative averages ± standard
deviation (SD). (B) Copy numbers of the four reprogramming factor transgenes
(OCT4, SOX2, KLF-4
and c-MYC) were determined in Huv-iPS cell lines by
quantitative real-time PCR as described in Methods. Data were presented as the copy number of both
endogenous gene (2 copies/genome) and transgene (the portion higher than 2
copies/genome) for each reprogramming factor. Two human ES cell lines (H9,
H1; white bars) were used as negative controls for transgenes. The copy
numbers of transgenes in three Huv-iPS cell lines (Huv-iPS4F1, Huv-iPS4F3,
Huv-iPS4F6; black bars) were compared to five other characterized iPS cell
lines (gray bars) obtained from fibroblasts (FiPS4F5), astrocytes
(ASTiPS4F5) or keratinocytes (KiPS4F2, KiPS4FA, KiPS4FB). Data are shown as
the relative averages ± standard deviation (SD).
Reprogramming factor expression and transgene integration in Huv-iPS
cells.
(A) Gene expression levels of the endogenous and total levels of
OCT4, SOX2, KLF-4 and
c-MYC in Huv-iPS cell lines, ES cell controls (H1 and
H9 cell lines), somatic cells (keratinocytes and HUVECs) or somatic cells 3
days after KOSM infection. Individual real-time PCR reactions were
normalized to GAPDH, and plotted relative to the expression
level in HUVECs. Data are shown as the relative averages ± standard
deviation (SD). (B) Copy numbers of the four reprogramming factor transgenes
(OCT4, SOX2, KLF-4
and c-MYC) were determined in Huv-iPS cell lines by
quantitative real-time PCR as described in Methods. Data were presented as the copy number of both
endogenous gene (2 copies/genome) and transgene (the portion higher than 2
copies/genome) for each reprogramming factor. Two humanES cell lines (H9,
H1; white bars) were used as negative controls for transgenes. The copy
numbers of transgenes in three Huv-iPS cell lines (Huv-iPS4F1, Huv-iPS4F3,
Huv-iPS4F6; black bars) were compared to five other characterized iPS cell
lines (gray bars) obtained from fibroblasts (FiPS4F5), astrocytes
(ASTiPS4F5) or keratinocytes (KiPS4F2, KiPS4FA, KiPS4FB). Data are shown as
the relative averages ± standard deviation (SD).We next evaluated pluripotency markers of each Huv-iPS cell line at the protein
level. Cell surface protein marker analysis demonstrated that Huv-iPS cells
expressed the pluripotent markers Tra-1-60, Tra1-81 and SSEA-4, and had lost
expression of the endothelial marker CD31. Furthermore, the parental HUVEC
populations were negative for CD45 and CD34, ruling out the contribution of any
possible residual hematopoietic cells obtained from HUVEC preparations in the high
reprogramming efficiencies observed (Figure 4A). To further assess the overall profile of Huv-iPS cell lines
relative to ES cells, we analyzed the expression of several genes involved in
various aspects of stem cell biology (see Methods). As shown in Figure 4B, using the Pearson correlation coefficient to measure the
distance between the different sets of values, individual Huv-iPS cell lines had
stem cell gene expression profiles that were as similar to ES cell controls as
individual ES cell lines were to one another.
Figure 4
Huv-iPS cells express pluripotent markers.
(A) Flow cytometry analysis for pluripotency (Tra-1-60, Tra-1-81, SSEA-4),
hematopoietic (CD45, CD34) or endothelial (CD31) markers as indicated, for
all Huv-iPS cell lines, and the appropriate positive controls (H9 ES cells,
hematopoietic cells, or HUVECs, respectively). Percentages were determined
relative to the appropriate isotype control (black lines) for each cell
type. (B) Ct values obtained from real-time PCR analysis of a defined set of
genes (see Methods) were normalized to
GAPDH expression, and plotted to generate a graphical
representation of the similarity between the different cell lines as
indicated. r = Pearson coefficient.
Huv-iPS cells express pluripotent markers.
(A) Flow cytometry analysis for pluripotency (Tra-1-60, Tra-1-81, SSEA-4),
hematopoietic (CD45, CD34) or endothelial (CD31) markers as indicated, for
all Huv-iPS cell lines, and the appropriate positive controls (H9 ES cells,
hematopoietic cells, or HUVECs, respectively). Percentages were determined
relative to the appropriate isotype control (black lines) for each cell
type. (B) Ct values obtained from real-time PCR analysis of a defined set of
genes (see Methods) were normalized to
GAPDH expression, and plotted to generate a graphical
representation of the similarity between the different cell lines as
indicated. r = Pearson coefficient.As a final stringent analysis of Huv-iPS cell pluripotency, we evaluated the
potential of each Huv-iPS cell line to differentiate into the three embryonic germ
layers in vitro and in vivo. Immunofluorescence
analysis of embryoid bodies differentiated from Huv-iPS cells showed the presence of
markers for endoderm, ectoderm and mesoderm lineages (Figure 5A). Injection of Huv-iPS cell lines into
immunocompromised mice produced teratomas, which contained tissues from all three
embryonic germ layers (Figure 5B,
5C). Lastly, Huv-iPS cell lines displayed a normal karyotype (Figure 5D), and have been
maintained in feeder-free conditions for over 40 passages. These collective results
demonstrate the successful reprogramming of HUVECs into iPS cells, with the fastest
kinetics and one of the highest efficiencies reported for any human somatic cell to
date.
Figure 5
Huv-iPS cell lines demonstrate pluripotency in vitro and
in vivo.
(A) Huv-iPS cell lines were used in embryoid body (EB)-mediated
differentiation assays, and stained by immunofluorescence for endodermal
(FoxA2), ectodermal (Tuj-1), or mesodermal (alpha smooth muscle actin
(ASMA)) markers representing each embryonic germ layer.
4,6-Diamidino-2-phenylindole (DAPI) staining shows nuclei. (B–C)
Huv-iPS cell lines were injected into immunocompromised mice and analyzed
for teratoma formation. Resulting teratomas were analyzed for tissues
representing each of the three embryonic germ layers by (B) fluorescent
imaging (endodermal markers FoxA2 and α-fetoprotein (AFP), upper panels;
ectodermal markers GFAP and TuJ-1, middle panels; mesodermal markers alpha
sarcomeric actin (ASA) and alpha smooth muscle actin (ASMA), lower panels;
nuclei are stained with DAPI or by (C) hematoxlin and eosin staining
(endoderm, upper panels; ectoderm, middle panels; or mesoderm, lower
panels). All images for individual lines were obtained from a single tumor,
and were acquired using a 40× objective. (D) Karyotype analysis
demonstrating that Huv-iPS cell lines maintain normal chromosomal
integrity.
Huv-iPS cell lines demonstrate pluripotency in vitro and
in vivo.
(A) Huv-iPS cell lines were used in embryoid body (EB)-mediated
differentiation assays, and stained by immunofluorescence for endodermal
(FoxA2), ectodermal (Tuj-1), or mesodermal (alpha smooth muscle actin
(ASMA)) markers representing each embryonic germ layer.
4,6-Diamidino-2-phenylindole (DAPI) staining shows nuclei. (B–C)
Huv-iPS cell lines were injected into immunocompromised mice and analyzed
for teratoma formation. Resulting teratomas were analyzed for tissues
representing each of the three embryonic germ layers by (B) fluorescent
imaging (endodermal markers FoxA2 and α-fetoprotein (AFP), upper panels;
ectodermal markers GFAP and TuJ-1, middle panels; mesodermal markers alpha
sarcomeric actin (ASA) and alpha smooth muscle actin (ASMA), lower panels;
nuclei are stained with DAPI or by (C) hematoxlin and eosin staining
(endoderm, upper panels; ectoderm, middle panels; or mesoderm, lower
panels). All images for individual lines were obtained from a single tumor,
and were acquired using a 40× objective. (D) Karyotype analysis
demonstrating that Huv-iPS cell lines maintain normal chromosomal
integrity.
Discussion
Our findings demonstrating rapid and highly efficient reprogramming of HUVECs are in
contrast to a previous report, which showed that KOSM infection of HUVECs generated
iPS cell colonies after more than two weeks, with a reprogramming efficiency that
was 100-fold lower (∼0.03%) [20]. Very recent studies also
demonstrated that iPS cells could be generated from HUVECs at <0.03%
efficiency. However, in these reports reprogramming was performed using only SOX2
and OCT4 [21], or OCT4
and a combination of chemical compounds [22]; thus, the use of fewer factors
are likely contributing to the lower reprogramming efficiencies and delayed kinetics
observed in these instances [21], [22].Although the reasons for some of these discrepancies remain unclear, variations in
somatic cell sources, virus quality and infection protocols are known variables in
reprogramming [16]. However, we have tested various HUVEC lots and
consistently found reprogramming efficiency to be ∼2.5–3% with
initial colony appearance ∼day 6, and thus it is unlikely that the source of
HUVECs is causing these differences (Figure 2C). Additionally, we performed parallel transduction experiments
with human keratinocytes and fibroblasts, and found that the observed reprogramming
efficiencies and kinetics correlated with what has been previously reported in the
literature (Figure 2C, data not
shown) [2],
[3], [13]. Thus, these
collective data indicate that our reprogramming experiments are accurately assessing
the reprogramming capabilities of HUVECs.Our laboratory and others have reported the generation of iPS cells from human cord
blood [23],
[24], which
provides the advantage of an available banked HLA-typed somatic cell source for
reprogramming. Furthermore, iPS cells obtained from embryonic somatic sources have
been shown to be safer than those obtained from adult cells [25], which have been subjected to
mutagenic events during aging. HUVECs are isolated from newborn's umbilical
cord with no risk to the donor, can be rapidly prepared without purification steps,
and stored in large quantities [9]. Thus, HUVECs could be collected by cord blood banks, to
serve as an alternative HLA-typed reprogramming source, since a reasonable amount of
HLA-typed iPS cell lines could provide a beneficial match for a considerable
percentage of the population [26], [27]. This would also enable the reserve of valuable cord
blood samples for use in bone marrow transplantation. The rapid and efficient
generation of iPS cells from HUVECs could also provide an important tool to discern
the mechanisms governing reprogramming. These combined reasons make HUVECs an
attractive somatic source for therapeutic application, and for studying the
reprogramming process.
Authors: Tenneille E Ludwig; Veit Bergendahl; Mark E Levenstein; Junying Yu; Mitchell D Probasco; James A Thomson Journal: Nat Methods Date: 2006-08 Impact factor: 28.547
Authors: Junying Yu; Maxim A Vodyanik; Kim Smuga-Otto; Jessica Antosiewicz-Bourget; Jennifer L Frane; Shulan Tian; Jeff Nie; Gudrun A Jonsdottir; Victor Ruotti; Ron Stewart; Igor I Slukvin; James A Thomson Journal: Science Date: 2007-11-20 Impact factor: 47.728
Authors: J A Thomson; J Itskovitz-Eldor; S S Shapiro; M A Waknitz; J J Swiergiel; V S Marshall; J M Jones Journal: Science Date: 1998-11-06 Impact factor: 47.728
Authors: Craig J Taylor; Eleanor M Bolton; Susan Pocock; Linda D Sharples; Roger A Pedersen; J Andrew Bradley Journal: Lancet Date: 2005-12-10 Impact factor: 79.321
Authors: Athanasia D Panopoulos; Oscar Yanes; Sergio Ruiz; Yasuyuki S Kida; Dinh Diep; Ralf Tautenhahn; Aída Herrerías; Erika M Batchelder; Nongluk Plongthongkum; Margaret Lutz; W Travis Berggren; Kun Zhang; Ronald M Evans; Gary Siuzdak; Juan Carlos Izpisua Belmonte Journal: Cell Res Date: 2011-11-08 Impact factor: 25.617
Authors: Imbisaat Geti; Mark L Ormiston; Foad Rouhani; Mark Toshner; Mehregan Movassagh; Jennifer Nichols; William Mansfield; Mark Southwood; Allan Bradley; Amer Ahmed Rana; Ludovic Vallier; Nicholas W Morrell Journal: Stem Cells Transl Med Date: 2012-11-29 Impact factor: 6.940